Literature DB >> 22980591

Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT.

Mohammad A Kobeisy1, Khairy H Morsy, Mohammad Galal, Sohair K Sayed, Mohammad M Ashmawy, Fattahallah M Mohammad.   

Abstract

BACKGROUND AND STUDY AIMS: Egypt has the highest prevalence of hepatitis C in the world. Alpha-foetoprotein (AFP) is important in the diagnosis of hepatocellular carcinoma (HCC), but elevated AFP levels have also been observed in chronic hepatitis C (CHC) without HCC. We evaluated the clinical correlation between elevated AFP levels and CHC. We analysed data from a population-based cohort of patients with hepatitis C virus (HCV) infection to assess the prevalence of elevated serum AFP, to determine its association with clinical and virologic parameters and with clinical outcomes. PATIENTS AND METHODS: From December 2009 to April 2011, 121 patients with no evidence of HCC with regular abdominal ultrasound or other imaging studies (multislice computed tomography (MSCT) or magnetic resonance imaging (MRI)) were controlled by a chart review.
RESULTS: The prevalence of elevated AFP ≥10ngml(-1) was 11.6%. Univariate analysis revealed that fibrosis stage III/IV, alanine aminotransferase (ALT) more than 45IUl(-1) and platelet count less than 150×10(9) l(-1) were significantly associated with elevated AFP. Multivariate analysis revealed that the independent variable associated with elevated serum AFP was fibrosis stage III/IV, p=0.015. Multivariate analysis also revealed that AST>45IUl(-1) and AFP ≥10 ngml(-1) were associated with advanced fibrosis using a cut-off AFP value >10 ngml(-1). The sensitivity and specificity of diagnosing fibrosis score III/IV were 26.1% and 97.3%, respectively.
CONCLUSIONS: Elevated AFP levels were observed in 11.65% of patients with CHC. Elevated AFP levels correlated positively with fibrosis stage III/IV; ALT elevation, thrombocytopenia and AFP ≥10 ngml(-1) were associated with advanced fibrosis. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22980591     DOI: 10.1016/j.ajg.2012.06.004

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  11 in total

Review 1.  Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis.

Authors:  Qing Pang; Kai Qu; Jian-Bin Bi; Su-Shun Liu; Jing-Yao Zhang; Si-Dong Song; Ting Lin; Xin-Sen Xu; Yong Wan; Ming-Hui Tai; Hao-Chen Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

2.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

3.  Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.

Authors:  Koji Takayama; Norihiro Furusyo; Eiichi Ogawa; Hiroaki Ikezaki; Motohiro Shimizu; Masayuki Murata; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

4.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

5.  Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.

Authors:  Mehdi Assmar; Sara Yeganeh; Fariborz Mansourghanaei; Nour Amirmozafari
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

6.  MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma.

Authors:  Hussein Ahmed El Mahdy; Ismail Abdelshafy Abdelhamid; Ahmed Ibrahim Amen; Eman Abdelsameea; Mona M Hassouna
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

7.  The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia.

Authors:  Chyntia Olivia Maurine Jasirwan; Alessa Fahira; Lianda Siregar; Imelda Loho
Journal:  BMC Gastroenterol       Date:  2020-07-09       Impact factor: 3.067

Review 8.  The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Qing Pang; Kai Qu; Jing-Yao Zhang; Si-Dong Song; Su-Shun Liu; Ming-Hui Tai; Hao-Chen Liu; Chang Liu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

9.  Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis.

Authors:  Xia Ying; Su-xia Han; Jun-lan Wang; Xia Zhou; Gui-hua Jin; Long Jin; Hao Wang; Lei Wu; Jianying Zhang; Qing Zhu
Journal:  Diagn Pathol       Date:  2013-08-05       Impact factor: 2.644

Review 10.  Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.

Authors:  Hira Hanif; Mukarram Jamat Ali; Ammu T Susheela; Iman Waheed Khan; Maria Alejandra Luna-Cuadros; Muzammil Muhammad Khan; Daryl Tan-Yeung Lau
Journal:  World J Gastroenterol       Date:  2022-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.